PubMed Health⌕ Search

Biomedical subjects

D Schorn

Publications and source records attributed to D Schorn.

At least 19 recordsLinked to original sources

Assessing impairment and disability for syndromes presenting with chronic fatigue.

Many disability claims are based on the subjective symptom of fatigue, which can be caused by a wide spectrum of diagnoses including fibromyalgia, chronic fatigue syndrome and cardiopulmonary diseases. Chronic pain is very often a compounding problem. It is vital for every insurer to have fair and objective criteria to distinguish between invalid claims and those with merit. This review article proposes objective tools and parameters to achieve this goal.

Activities of Daily Living↗

Tenoxicam in soft-tissue rheumatism.

A randomized double-blind trial with tenoxicam 10 mg/d and 20 mg/d and placebo was carried out for 2 weeks in 90 patients suffering from various extra-articular inflammatory conditions. Statistical analysis revealed significant differences in favour of tenoxicam as regards improvement of all parameters with an intensity which was moderate or severe at baseline, e.g. tenderness, mobility pain, functional limitation. The efficacy of tenoxicam at both dosages was similar (no statistically significant difference). Tenoxicam was well tolerated but some mild adverse reactions were observed in all three treatment groups.

Adult↗

A comparative study of isoxicam and naproxen in rheumatoid arthritis.

A 4-week parallel-group, double-blind comparison of isoxicam 200 mg once daily and naproxen 250 mg 3 times daily was carried out on 30 patients with classic or definite rheumatoid arthritis. Fifteen patients were randomly assigned to each treatment group. The articular index, scoring on a pain scale and morning stiffness were significantly reduced after 2 and 4 weeks of treatment with both drugs. Grip strength was significantly increased after 4 weeks of naproxen treatment. The mean increase in grip strength was also comparable in isoxicam-treated patients, but did not reach statistical significance. Joint swelling and walking times showed improvement in both groups. One patient withdrew from isoxicam treatment with a pruritic rash considered to be drug-related and another stopped taking isoxicam because of dizziness, nausea and vomiting--also probably drug-related. Eight other patients, 4 treated with isoxicam and 4 with naproxen, reported adverse reactions associated with the digestive system. In this study isoxicam 200 mg taken once daily was similar in efficacy to and was associated with a similar incidence of adverse reactions as naproxen 250 mg taken 3 times daily. Both drugs were effective in the treatment of rheumatoid arthritis and were well tolerated.

Adult↗

Osteoporosis in the rheumatoid hand--the effects of treatment with D-penicillamine and oral gold salts.

Osteoporosis is a common and important feature of rheumatoid disease which can be further influenced by the treatment administered. D-penicillamine, a lathyritic agent, can also theoretically hasten the osteoporotic process through its effect on collagen metabolism. In the present study the effects of the long-term second-line drugs D-penicillamine and oral gold (Auranofin) on bone density are presented. All the patients studied lost bone mineral over the 3-year period, but continuous D-penicillamine therapy for 1 year reversed this trend. Oral gold did not have the same effect. Measurements of bone density are an accurate indirect measurement of hand function, and there is a good correlation between hand function and the progress of osteoporosis. It is therefore suggested that treatment with D-penicillamine reverses the tendency to lose bone mineral improving synovitis, thus leading to improved hand function.

Anti-Inflammatory Agents↗

An oral gold formulation in rheumatoid arthritis. A 12-month follow-up report.

Oral gold(Auranofin; SKF) 6 mg/d has been used in an open study in 31 patients with active rheumatoid disease, 19 of whom have been on continuous treatment for 1 year. Four of these patients were considered to be in remission and 9 had a good clinical response to treatment. Four showed only minimal improvement and 2 did not improve at all. There were, however, no changes in the biochemical parameters of inflammation, e.g. haemoglobin concentration, erythrocyte sedimentation rate, platelet count and rheumatoid factor, or in renal and hepatic function. Of the 31 patients, 9 (29%) have discontinued treatment but only 3 (9.7%) because of side-effects. Minor side-effects have been fairly common, occurring in 19 patients (61%), and included skin rashes and pruritus, diarrhoea and loose stools, nausea, stomatitis and thrombocytopenia or leucopenia. Oral gold would seem to be a safer, less potent form of chrysotherapy than parenteral gold.

Administration, Oral↗

Septic polyarthritis due to Bacteroides fragilis in a patient with rheumatoid arthritis. A case report.

Gram-negative septic arthritis is an uncommon but serious complication of rheumatoid arthritis and is usually mono-articular. The present case is unusual in that a septic polyarthritis due to Bacteroides fragilis developed in nine joints. The organism was grown only in anaerobic synovial fluid and blood cultures. The patient recovered after treatment which included repeated needle aspirations of the joints under anaesthesia and oral metronidazole (Flagyl; Maybaker). Any patient with rheumatoid arthritis who develops an acute flare-up of disease in one or more joints should have these aspirated to exclude the possibility of septic arthritis. Both anaerobic and aerobic cultures of synovial fluid and blood should be done. Prompt antibiotic treatment and joint drainage are the cornerstones of treatment.

Arthritis, Infectious↗

[Principles of treatment of gout and hyperuricemia].

Gout can be considered to be a group of diseases that are typified by acute arthritis, tophi and kidney stones. The acute attacks of arthritis should be treated with standard anti-inflammatory agents and the patient should receive maintenance therapy after the second acute attack. The dangers of asymptomatic hyperuricaemia are acute arthritis and uric acid kidney stones. Patients should be treated when the serum uric acid level is greater than 0,54 mmol/l or if the urinary uric acid excretion is greater than 4,2 mmol/l/24 h.

Acute Disease↗

Diflunisal in rheumatoid arthritis. A controlled trial.

Diflunisal (Dolobid; Frosst-MSD) is an acetylsalicylic acid (ASA) derivative and has potential advantages over ASA, e.g. a longer half-life, higher potency and better tolerance. It has been shown to be effective as an analgesic in a variety of conditions. In a 12-week double-blind controlled trial diflunisal was compared with naproxen (Naprosyn; Syntex) in patients with rheumatoid arthritis. Suitable efficacy data were only available at week 4 owing to a number of withdrawals from the naproxen group. Both drugs, however, produced improvement in all the indices measured. At week 12 the initial improvement in the diflunisal group was maintained. Side-effects from diflunisal were mainly related to the gastro-intestinal tract but were not of serious nature; tinnitus and deafness did not occur. Diflunisal is an effective analgesic and also has anit-inflammatory action. It is a useful addition to the range of aspirin derivatives available for the treatment of rheumatoid arthritis.

Adult↗

Carprofen in soft-tissue rheumatism. A controlled trial.

A randomized double-blind clinical trial was carried out comparing carprofen (RO 20-5720) 300 mg/d and indomethacin 75 mg/d in patients with extra-articular inflammatory processes. The drugs were given for 7 days. In general carprofen appears to be well tolerated, and at the dosage used its efficacy was good and equal to that of indomethacin.

Adult↗

Indomethacin or sulindac at night in rheumatoid arthritis.

The effects of indomethacin and sulindac in relieving troublesome morning stiffness and nighttime pain were tested in a double-blind cross-over trial. Thirteen of the 17 patients who completed the trial preferred indomethacin which was found to be superior to sulindac in all the parameters tested. Sulindac did, however, have some beneficial effect and can be used as an alternative to indomethacin when this drug cannot be used as the agent of first choice.

Adult↗

Skin collagen biosynthesis in patients with rheumatoid arthritis treated with D-penicillamine.

Collagen biosynthesis was measured in skin biopsies taken from 13 patients with rheumatoid arthritis before and after at least 6 months' continuous treatment with D-penicillamine, 1.0 g/day. There was a significant 36% reduction in mean collagen biosynthesis (p less than 0.0125) as assayed by 14C-hydroxyproline formation from 14C-proline during 24 h of tissue culture. The changes in 14C-hydroxyproline formation were correlated with the total doses of D-penicillamine taken (r = 0.71, p less than 0.01) and the falls in ESR (r = 0.72, p less than 0.01). No significant change in general protein syntehsis was observed. 500 microgram/mlD-penicillamine added to skil cultures in vitro inhibited both collagen and general protein synthesis (p less than 0.01). It is suggested that the clinical improvement induced by D-penicillamine could reflect an inhibition of collagen proliferation in the synovium.

Adult↗

Bone density and the carpal tunnel syndrome.

Bone density was studied in ten patients before and after release of an idiopathic carpal tunnel syndrome. A corticomedullary ratio was measured at the mid-point of the metacarpals and proximal phalanges of both hands. There was a significant increase in the mean bone density over the period of observation in the thumb and middle finger metacarpals and in the index, middle, and ring finger proximal phalanges of the operated hand. There was no significant increase in the density of either metacarpal or proximal phalanx on the non-operated side. Release of the carpal tunnel syndrome provides not only symptomatic relief but also leads to increased bone density.

Adult↗